The City Council unanimously voted to ban the use of a class of rat poisons known as second-generation anticoagulant rodenticides, or SGARs, on city-owned property after a public hearing ...

Global Personalized Medicine Market size is expected to be worth around USD 1,103.6 Bn by 2032 from USD 553.8 Bn in 2023, growing at a CAGR of 8.2% ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

High blood pressure stands among the leading causes of stroke, yet many people fail to recognize the critical importance of ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

A New Therapeutic Target for a Lethal Form of Heart Failure ... 2025 — Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K antagonist will ...